CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma

American Journal of Clinical Pathology

Volumn 132, Issue 4, 2009, Pages 531-538

  Saad, Reda S ^a,b   Ismiil, Nadia ^b   Dubé, Valérie ^b   Nofech Mozes, Sharon ^b   Khalifa, Mahmoud A ^b  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

CDX 2; Cervical adenocarcinoma; Intestinal differentiation

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; PROTEIN P16; TRANSCRIPTION FACTOR CDX2; CDX 2 3 PROTEIN; CDX-2-3 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HOMEODOMAIN PROTEIN; TRANSACTIVATOR PROTEIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA; RECTUM TUMOR; STAINING; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; BIOSYNTHESIS; INTESTINE TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INTESTINAL NEOPLASMS; KERATIN-20; KERATIN-7; RECTAL NEOPLASMS; TRANS-ACTIVATORS; UTERINE CERVICAL NEOPLASMS;

EID: 70349563903     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP7E5ASGOENPFP     Document Type: Article

References (44)

1. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer. 2003;39:1990-2005. (Pubitemid 37297755)
2. van de Wouw AJ, Jansen RI, Speel EJ, et al. The unknown biology of the unknown primary tumor: a literature review. Ann Oncol. 2003;14:191-196. (Pubitemid 36305428)
3. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785. (Pubitemid 38529553)
4. Park S-Y, Kim B-H, Kim J-H, et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med. 2007;131:1561-1567.
5. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem Mol Morphol. 1995;3:99-107.
6. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972. (Pubitemid 30736647)
7. Pecciarini L, Cangi MG, Doglioni C. Identifying the primary sites of metastatic carcinoma: the increasing role of immunohistochemistry. Curr Diagn Pathol. 2001;7:168-175. (Pubitemid 32906449)
8. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998;29:491-497. (Pubitemid 28213469)
9. Wauters CAP, Smedts F, Gerrits LG, et al. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol. 1995;26:850-855.
10. Walters JR, Howard A, Rumble HE, et al. Differences in expression of homeobox transcription factors in proximal and distal human small intestine. Gastroenterology. 1997;113:472-477. (Pubitemid 27351773)
11. James R, Erler T, Kazenwadel J. Structure of the murine homeobox gene, cdx-2: expression in embryonic and adult intestinal epithelium. J Biol Chem. 1994;269:15229-15237. (Pubitemid 24198371)
12. Werling RW, Yaziji H, Bacchi CE, et al. CDX-2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310. (Pubitemid 36245795)
13. Moskaluk CA, Zhang H, Powell SM, et al. CDX-2 expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol. 2003;16:913-919. (Pubitemid 37152021)
14. Barbareschi M, Murer B, Colby TV, et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol. 2003;27:141-149. (Pubitemid 36152222)
15. Cathro HP, Mills SE. Immunophenotypic differences between intestinal-type and low grade papillary sinonasal adenocarcinomas: an immunohistochemical study of 22 cases utilizing CDX-2 and MUC2. Am J Surg Pathol. 2004;28:1026-1032.
16. Fraggetta F, Pelosi G, Cafici A, et al. CDX-2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch. 2003;443:782-786. (Pubitemid 38030633)
17. Sullivan LM, Smolkin ME, Frierson HF, et al. Comprehensive evaluation of CDX-2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology. Am J Surg Pathol. 2008;32:1608-1612.
18. Wells M, Nesland JM, Oslor AG, et al. Epithelial tumours of the uterine cervix. In: Tavassoli FA, Deville P, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:260-279.
19. Raspollini MR, Baroni G, Taddei A, et al. Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix: an investigation using cdx-2 and a limited immunohistochemical panel. Arch Pathol Lab Med. 2003;127:1586-1590. (Pubitemid 37517469)
20. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403-439. (Pubitemid 34535443)
21. Berezowski K, Stastny J, Kornstein M. Cytokeratin 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol. 1996;9:426-429. (Pubitemid 26152008)
22. Maeda T, Kajiyama K, Adachi E, et al. The expression of cytokeratins 7, 19, 20 in primary and metastatic carcinomas of the liver. Mod Pathol. 1996;9:901-909. (Pubitemid 26319720)
23. Ramaekers F, van Niekerk C, Poels L, et al. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am J Pathol. 1990;136:641-655. (Pubitemid 20105931)
24. Logani S, Oliva E, Amell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol. 2005;18:19-25. (Pubitemid 40128090)
25. Raspollini MR, Amunni G, Villanucci A, et al. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases. Appl Immunohistochem Mol Morphol. 2004;12:127-131. (Pubitemid 38788761)
26. Tornillo L, Moch H, Diener PA, et al. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J Clin Pathol. 2004;57:641-643. (Pubitemid 38725768)
27. Vang R, Gown AM, Barry TS, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol. 2006;30:1130-1139. (Pubitemid 44299346)
28. Vang R, Gown AM, Wu LS, et al. Immunohistochemical expression of CDX-2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol. 2006;19:1421-1428. (Pubitemid 44624160)
29. McCluggage WG, Shah R, Connolly LE, et al. Intestinal type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX-2. Int J Gynecol Pathol. 2008;27:92-100. (Pubitemid 351627980)
30. Keating JT, Cviko A, Reithdorf S, et al. Ki-67, cyclin E and p16INK4A are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001;25:884-891. (Pubitemid 32594981)
31. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284. (Pubitemid 32225381)
32. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741-1748. (Pubitemid 28550662)
33. Ramalingam P, Hart WR, Goldblum JR. Cytokeratin subset immunostaining in rectal adenocarcinoma and normal anal glands. Arch Pathol Lab Med. 2001;125:1074-1077.
34. Zhang PJ, Shah M, Spiegel GW, et al. Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2003;11:306-310.
35. Goldblum JR, Hart WR. Perianal Paget's disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol. 1998;22:170-179.
36. Nowak MA, Guerriere-Kovach P, Pathan A, et al. Perianal Paget's disease: distinguishing primary and secondary lesions using immunohistochemical studies including gross cystic disease fluid protein-15 and cytokeratin 20 expression. Arch Pathol Lab Med. 1998;122:1077-1081. (Pubitemid 29009399)
37. Saad RS, Essig DL, Silverman JF, et al. Diagnostic utility of CDX-2 expression in separating metastatic gastrointestinal adenocarcinoma from other metastatic adenocarcinomas in fine needle aspiration cytology using cell block. Cancer. 2004;102:168-173.
38. Saad RS, Rowsell C, Khalifa MA, et al. CDX-2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinomas [published online ahead of print December 18, 2008]. Appl Immunohistochem Mol Morphol. 2009;17:196-201.
39. Groisman GM, Meir A, Sabo E. The value of CDX-2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int J Gynecol Pathol. 2004;23:52-57. (Pubitemid 38018238)
40. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer. 1999;85:171-177. (Pubitemid 29031372)
41. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005;29:281-294. (Pubitemid 40321963)
42. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004;28:160-167. (Pubitemid 38124723)
43. Hadzisejdć I, Krasević M, Haller H, et al. Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. Coll Antropol. 2007;31(suppl 2):97-102.
44. Plunkett M, Brestovac B, Thompson J, et al. The value of HPV DNA typing in the distinction between adenocarcinoma of endocervical and endometrial origin. Pathology. 2003;35:397-401. (Pubitemid 37310980)